Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-018663
Filing Date
2024-05-10
Accepted
2024-05-10 16:31:01
Documents
54
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 575586
2 ex31-1.htm EX-31.1 18955
3 ex31-2.htm EX-31.2 19327
4 ex32-1.htm EX-32.1 11040
  Complete submission text file 0001493152-24-018663.txt   3332866

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE impb-20240331.xsd EX-101.SCH 25137
6 XBRL CALCULATION FILE impb-20240331_cal.xml EX-101.CAL 38501
7 XBRL DEFINITION FILE impb-20240331_def.xml EX-101.DEF 83575
8 XBRL LABEL FILE impb-20240331_lab.xml EX-101.LAB 215667
9 XBRL PRESENTATION FILE impb-20240331_pre.xml EX-101.PRE 170422
58 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 416604
Mailing Address 1400 BROADFIELD BLVD. SUITE 130 HOUSTON TX 77084
Business Address 1400 BROADFIELD BLVD. SUITE 130 HOUSTON TX 77084 585 232 1500
IMPACT BIOMEDICAL INC. (Filer) CIK: 0001834105 (see all company filings)

EIN.: 853926944 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 333-253037 | Film No.: 24935452
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)